scholarly journals Management of Respiratory Syncytial Virus Bronchiolitis: 2015 Survey of Members of the European Society for Paediatric Infectious Diseases

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Elliott J. Carande ◽  
Andrew J. Pollard ◽  
Simon B. Drysdale
Keyword(s):  
Respiratory Syncytial Virus ◽  
Infectious Diseases ◽  
European Society ◽  
English Language ◽  
Supplemental Oxygen ◽  
Draft Guideline ◽  
Treatment Practices ◽  
The United Kingdom ◽  
Similar Survey ◽  
Syncytial Virus

In 1995, the European Society for Paediatric Infectious Diseases (ESPID) carried out a survey of its members to assess the variation in management of respiratory syncytial virus (RSV) bronchiolitis. The aim of the current study was to carry out a similar survey 20 years later to assess how the management had changed. An electronic, structured, English language survey, based on the United Kingdom National Institute for Health and Care Excellence (NICE) bronchiolitis draft guideline, was sent to ESPID members in March 2015. Questions asked included information on treatment practices of infants with bronchiolitis and doctor demographics. We received responses from 135 doctors (14% of the ESPID members) who worked in 115 hospitals. 56% of the doctors used a written guideline to manage bronchiolitic infants. All doctors stated that they isolated individually or in cohorts all hospitalised bronchiolitis infants. The level of oxygen saturation suggested as an indication to administer supplemental oxygen varied between <89% and <95%. We found significant reductions in the use of ribavirin, bronchodilators, and corticosteroids from 1995 to 2015 (ribavirin 57% to 13%,P<0.0001; bronchodilators 95% to 82%,P=0.0024; corticosteroids 81% to 45%,P<0.0001). Although variability in management remains high, encouragingly significantly fewer doctors are prescribing ribavirin, bronchodilators, and corticosteroids compared to 20 years ago.

Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease

2003 ◽  
Vol 13 (5) ◽  
pp. 420-423 ◽  
Author(s):  
Robert Tulloh ◽  
Michael Marsh ◽  
Michael Blackburn ◽  
Frank Casey ◽  
Warren Lenney ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Cardiac Disease ◽  
Pulmonary Blood Flow ◽  
Surgical Intervention ◽  
Randomised Trial ◽  
Pulmonary Complications ◽  
The United Kingdom ◽  
Congenital Cardiac Disease ◽  
Syncytial Virus

New data are emerging on the use of palivizumab as prophylaxis against infection with the respiratory syncytial virus in infants with congenital cardiac disease. Following a 4-year multicentre randomised trial, it was shown that prophylactic injections with palivizumab were effective and safe for such children. Prophylaxis consists of 5, monthly, intramuscular injections of palivizumab, at a dose of 15 mg/kg, given during the season for infection with the respiratory syncytial virus. Timing is at the discretion of the physician, depending on the onset of the season locally. It is suggested that, in the United Kingdom, this should be commenced in mid-September. To help clinicians to identify appropriate candidates for palivizumab, a working group of the British Paediatric Cardiac Association has developed recommendations.Infants, namely those under 1 year old, with congenital cardiac disease likely to benefit from prophylaxis include those with haemodynamically significant lesions, particularly increased pulmonary blood flow with or without cyanosis; pulmonary venous congestion, pulmonary hypertension or long-term pulmonary complications, residual haemodynamic abnormalities following medical or surgical intervention (patients who have undergone cardiopulmonary bypass should receive an injection as soon as they are medically stable), cardiomyopathy requiring treatment, and congenital cardiac disease likely to need hospital admission for medical or surgical intervention during the season of infection with the virus. Prophylaxis with palivizumab may also be indicated, at the discretion of the physician, in some children with complex cardiac disease over the age of 1 year. Children less likely to benefit from prophylaxis are those with haemodynamically insignificant disease, or those with lesions adequately corrected by medical or surgical intervention.

scholarly journals Respiratory Syncytial Virus in Infants and Children with Prader-Willi syndrome

2020 ◽  
Author(s):  
JL Miller ◽  
E Thornton
Keyword(s):  
Respiratory Syncytial Virus ◽  
Muscle Tone ◽  
The United States ◽  
Supplemental Oxygen ◽  
Lung Damage ◽  
Prader Willi Syndrome ◽  
Vaccine Recommendations ◽  
Routine Administration ◽  
Syncytial Virus ◽  
Contact Distribution

ABSTRACTBACKGROUNDPrader-Willi syndrome (PWS) is a complex disorder affecting approximately 1/15,000-1/30,000 people. Infants with PWS are at risk for serious complications with Respiratory Syncytial Virus (RSV) due to low muscle tone and a weakened pulmonary system.OBJECTIVESUnderstanding RSV incidence, hospitalization rates, lingering effects, and morbidity in children with PWS may help with planning health care, insurance and vaccine recommendations in children with PWS.METHODSLinks to volunteer surveys were provided via direct email and social media to families throughout the United States with children having PWS. The contact distribution lists were provided by PWSA(USA) and the Foundation for Prader-Willi Research.RESULTSA total of 220 surveys were completed by the parents/caregivers of children with PWS. Of those respondents, 60 (27.27%) had contracted the RSV virus during early childhood. Of those with RSV, 44 children required hospitalization, with 16 reporting multiple hospitalizations, some for several weeks. Of those with the virus, 22 required PICU admission, 10 required intubation, 20 needed CPAP, and 46 children needed supplemental oxygen during the infection. Of those who had contracted RSV, 42% were over age 1 year at the time of infection, and 17 children developed chronic lung issues after the RSV infection. The case lethality was 1.37%.Only 38% had received the RSV Synagis shot, and 19% received more than one season of the vaccination. Prematurity prevalence was only 28%, but 99% reported that their child had significant hypotonia.Approximately 30% of parents sited lack of insurance authorization or failure of the physician to recommend the treatment.CONCLUSIONSThe risk of contracting RSV for young children with PWS is high. The implications of contracting RSV include death or lung damage, along with high medical expenditures, which could be ameliorated with routine administration of the Synagis vaccine.

scholarly journals Using linked health data in international comparisons of infectious disease burden

2018 ◽  
Vol 3 (4) ◽  
Author(s):  
Rachel Reeves
Keyword(s):  
Infectious Disease ◽  
Respiratory Syncytial Virus ◽  
Infectious Diseases ◽  
Disease Burden ◽  
International Comparisons ◽  
Population Level ◽  
Health Data ◽  
Routinely Collected Data ◽  
Syncytial Virus ◽  
International Comparative

Linking population-level health databases – such as those on hospital admissions, GP consultations, prescriptions, maternal and perinatal data, and laboratory data – provides great opportunities to explore the epidemiology and burden of infectious diseases. Furthermore, comparing the epidemiology and burden of infectious diseases on an international scale is crucial in designing and implementing national and global prevention and control measures. However, substantial differences between countries in national health systems (including thresholds for hospital admission), as well as varying availability and quality of routinely collected data, can pose challenges when using linked population-level health databases to compare estimates of infectious disease burden between countries. This session aims to highlight and discuss the opportunities and challenges of international comparisons of infectious disease burden using linked population-level health data. This session will facilitate discussion of the methodological, ethical and resource challenges when using linked health data to produce internationally comparable estimates of the burden of infectious diseases. We will use as an example the ongoing work of the REspiratory Syncytial virus Consortium in Europe (RESCEU) – a large-scale collaborative project producing evidence to inform policymaking and regulatory decisions on novel respiratory syncytial virus (RSV) vaccines and therapeutics. The RESCEU project involves at least seven European countries each using linked routinely collected health data to produce national estimates of the health and economic burden of RSV, by age and risk group, for comparison. The results will highlight target populations for future vaccines and therapeutics, and provide a baseline estimate of the pre-vaccine era burden of disease that can be used to measure future vaccine impact. We will share the challenges faced in the RESCEU project with regards to using linked health data in international comparative work. We will then discuss, with relevance to other ongoing or future projects, how these challenges may be overcome. This session will generate ideas for procedures and tools for international comparative work using routinely collected data to investigate infectious diseases. This session will provide the opportunity to network with other researchers working in this area. We aim to facilitate the generation and dissemination of ideas for current and future projects, and therefore this session is likely to identify areas for potential future international collaborative work.

Sign in / Sign up

Export Citation Format

Share Document